

# Sara A Hurvitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1345207/publications.pdf>

Version: 2024-02-01

134  
papers

12,194  
citations

66343

42  
h-index

28297

105  
g-index

136  
all docs

136  
docs citations

136  
times ranked

11397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncology Practice, 2022, 18, e484-e494.	2.9	3
2	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. Clinical Cancer Research, 2022, 28, 1383-1390.	7.0	12
3	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 1854-1862.	7.0	5
4	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	1.2	11
5	Oncotype DX Recurrence Score in premenopausal women. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210810.	3.2	4
6	Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210855.	3.2	2
7	Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-01-P5-16-01.	0.9	0
8	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-15-P5-16-15.	0.9	2
9	Abstract P5-17-12: First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients. Cancer Research, 2022, 82, P5-17-12-P5-17-12.	0.9	0
10	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 2022, 386, 1143-1154.	27.0	474
11	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2~ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 2022, 28, 851-859.	7.0	90
12	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	2.5	15
13	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. Journal of Clinical Oncology, 2022, 40, 1000-1000.	1.6	9
14	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. Npj Breast Cancer, 2022, 8, .	5.2	25
15	Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. Journal of Clinical Oncology, 2022, 40, TPS1112-TPS1112.	1.6	0
16	TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS623-TPS623.	1.6	13
17	Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. Journal of Clinical Oncology, 2022, 40, 1071-1071.	1.6	7
18	Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, <i>HER2</i> -mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 179-190.	2.5	5
20	Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and â%¥2 prior HER2-directed regimens. , 2021, , .		1
21	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	7.0	49
22	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	27.0	601
23	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. <i>Nature Cancer</i> , 2021, 2, 400-413.	13.2	41
24	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1038-1038.	1.6	16
25	First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13043-e13043.	1.6	5
26	Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. <i>PLoS ONE</i> , 2021, 16, e0251163.	2.5	9
27	Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. <i>Breast</i> , 2021, 57, 95-103.	2.2	5
28	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	3.7	31
29	Finding the Sweet Spot in the Management of Early HER2+ Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 331-333.	2.9	1
30	Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?. <i>Clinical Breast Cancer</i> , 2021, 21, 526-531.	2.4	5
31	Anthracycline Use in <i>ERBB2</i>-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 975.	7.1	3
32	Cycling cancer persister cells arise from lineages with distinct programs. <i>Nature</i> , 2021, 596, 576-582.	27.8	236
33	Genomic Profiling of Premenopausal HR+ and HER2â€“ Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	3.0	15
34	Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 357-372.	2.5	2
35	A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 134.	5.2	25
36	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. <i>Oncologist</i> , 2020, 25, e214-e222.	3.7	39

#	ARTICLE	IF	CITATIONS
37	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2 <sup>+</sup> Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 566-580.	7.0	125
38	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
39	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
40	Talazoparib in Patients with a Germline <i>BRCA</i> -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. <i>Oncologist</i> , 2020, 25, e439-e450.	3.7	61
41	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
42	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). <i>Nature Communications</i> , 2020, 11, 5824.	12.8	42
43	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
44	Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 89.	5.0	74
45	HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1392-1393.	10.7	1
46	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
47	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. <i>Clinical Cancer Research</i> , 2020, 26, 1105-1113.	7.0	19
48	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	2.9	24
49	Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 233-248.	2.5	19
50	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1005-1005.	1.6	8
51	Oncology team perception and patient experience discordances in triple-negative breast cancer (TNBC) care.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19176-e19176.	1.6	0
52	SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1104-TPS1104.	1.6	3
53	Advances in Targeted Therapies for Triple-Negative Breast Cancer. <i>Drugs</i> , 2019, 79, 1217-1230.	10.9	71
54	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , 2019, 14, 647-656.	3.6	12

#	ARTICLE	IF	CITATIONS
55	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apolisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	7.0	76
56	Is the duration of adjuvant trastuzumab debate still clinically relevant?. <i>Lancet, The</i> , 2019, 393, 2565-2567.	13.7	5
57	Clinical features of pseudocirrhosis in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 409-417.	2.5	16
58	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	1.6	152
59	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	27.0	656
60	Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease. <i>Journal of Clinical Oncology</i> , 2019, 37, 1044-1046.	1.6	0
61	Dose intensification of chemotherapy for early breast cancer in the age of de-escalation. <i>Lancet, The</i> , 2019, 393, 1390-1392.	13.7	6
62	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancers—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. <i>Cancers</i> , 2019, 11, 1987.	3.7	12
63	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , 2019, 25, 2433-2441.	7.0	62
64	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	7.0	102
65	Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. <i>Cancer</i> , 2019, 125, 633-641.	4.1	31
66	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 500-500.	1.6	5
67	Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 548-548.	1.6	7
68	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS597-TPS597.	1.6	44
69	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS725-TPS725.	1.6	0
70	Implementation and dissemination of a shared mental model of palliative oncology.. <i>Journal of Clinical Oncology</i> , 2019, 37, 58-58.	1.6	0
71	Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 897-907.	4.1	77
72	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e205-e218.	2.4	5

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	10.7	333
74	Harnessing the immune system in the battle against breast cancer. <i>Drugs in Context</i> , 2018, 7, 1-21.	2.2	19
75	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133.	1.6	52
76	Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880733.	3.2	27
77	Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. <i>European Journal of Cancer</i> , 2018, 104, 160-168.	2.8	14
78	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018, 103, 147-154.	2.8	52
79	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 904-915.	10.7	648
80	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	27.0	1,472
81	Targeted Therapy for Premenopausal Women with HR+, HER2 <sup>+</sup> Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. <i>Clinical Cancer Research</i> , 2018, 24, 5206-5218.	7.0	40
82	Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1005-1005.	1.6	2
83	Dissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18575-e18575.	1.6	2
84	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	10.7	427
85	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 145-156.	2.5	1
86	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. <i>Breast Cancer Research</i> , 2017, 19, 47.	5.0	19
87	Optimal Management of Early and Advanced HER2 Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 76-92.	3.8	17
88	Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic. <i>Journal of Oncology Practice</i> , 2017, 13, e792-e799.	2.5	42
89	How are quality of life and work productivity associated with living longer with HER2+ metastatic breast cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 215-215.	1.6	2
90	Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1039-1045.	2.5	27

#	ARTICLE	IF	CITATIONS
91	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2â€œOverexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2016, 34, 2115-2124.	1.6	141
92	Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic. <i>Annals of Surgical Oncology</i> , 2016, 23, 634-641.	1.5	10
93	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	10.7	125
94	MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. <i>Cell Reports</i> , 2016, 14, 1590-1601.	6.4	174
95	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	1.6	32
96	A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. <i>Oncotarget</i> , 2016, 7, 78577-78590.	1.8	3
97	Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 520-30.	0.3	13
98	NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. <i>Systematic Reviews</i> , 2015, 4, 133.	5.3	2
99	New directions in the neoadjuvant treatment of HER2+ breast cancer. <i>Breast Cancer Management</i> , 2015, 4, 223-234.	0.2	0
100	Triple-negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, Publish Ahead of Print, 59-69.	2.0	71
101	Estrogen Receptor (ER) $\pm$ -regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression. <i>Journal of Biological Chemistry</i> , 2015, 290, 5566-5581.	3.4	61
102	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 816-829.	10.7	261
103	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190.	2.2	44
104	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 669-680.	2.5	46
105	The debate over post-mastectomy radiotherapy should continue. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 567-568.	27.6	7
106	Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 329.	0.7	19
107	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. <i>Clinical Cancer Research</i> , 2014, 20, 3507-3520.	7.0	100
108	nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 614-625.	7.7	39

#	ARTICLE	IF	CITATIONS
109	PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. <i>Journal of Neuro-Oncology</i> , 2014, 117, 7-13.	2.9	15
110	Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 202-209.	3.2	63
111	Afatinib in the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1039-1047.	4.1	33
112	The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>BMC Cancer</i> , 2014, 14, 307.	2.6	21
113	Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 320-326.	7.7	21
114	What Does the Future Hold for PI3K/AKT/mTOR Inhibitors in Breast Cancer?. <i>The Journal of Oncopathology</i> , 2014, 1, 73-81.	0.1	1
115	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. <i>Annals of Translational Medicine</i> , 2014, 2, 122.	1.7	32
116	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 437-446.	2.5	70
117	Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 603-609.	2.5	30
118	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1157-1163.	1.6	342
119	Current approaches and future directions in the treatment of HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 219-229.	7.7	120
120	Analysis of Fcγ3 Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3478-3486.	7.0	106
121	The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 235-245.	3.2	23
122	Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9144-9144.	1.6	1
123	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS649-TPS649.	1.6	11
124	Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint. <i>Cancer Treatment Reviews</i> , 2011, 37, 495-504.	7.7	15
125	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , The, 2011, 12, 369-376.	10.7	73
126	RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4286-4293.	1.6	379



#	ARTICLE	IF	CITATIONS
127	A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). <i>Clinical Breast Cancer</i> , 2010, 10, 307-312.	2.4	12
128	Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. <i>Journal of Clinical Oncology</i> , 2010, 28, 5110-5115.	1.6	203
129	What's positive about "triple-negative" breast cancer?. <i>Future Oncology</i> , 2009, 5, 1015-1025.	2.4	22
130	Rational management of endocrine resistance in breast cancer. <i>Cancer</i> , 2008, 113, 2385-2397.	4.1	79
131	Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 2729-2729.	1.4	5
132	Superior T Cell and Humoral Immunity Generated Against B Cell Lymphomas Using a Sulfhydryl-Based Idiotype Carrier Protein Conjugation Method.. <i>Blood</i> , 2006, 108, 232-232.	1.4	0
133	Current status of therapeutic vaccines for non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 2005, 17, 432-440.	2.4	34
134	Improvement of Idiotype Vaccine Efficacy Using a Sulfhydryl-Based Carrier Protein Conjugation Method: Results in Multiple Murine Lymphoma Models.. <i>Blood</i> , 2005, 106, 1481-1481.	1.4	0